Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
| Revenue (TTM) | $66.57B |
| Gross Profit (TTM) | $50.53B |
| EBITDA | $28.87B |
| Operating Margin | -0.24% |
| Return on Equity | 6.96% |
| Return on Assets | 11.90% |
| Revenue/Share (TTM) | $26.85 |
| Book Value | $16.99 |
| Price-to-Book | 8.71 |
| Price-to-Sales (TTM) | 5.51 |
| EV/Revenue | 5.16 |
| EV/EBITDA | 17.50 |
| Quarterly Earnings Growth (YoY) | -19.30% |
| Quarterly Revenue Growth (YoY) | 5.10% |
| Shares Outstanding | $2.47B |
| Float | $2.46B |
| % Insiders | 0.06% |
| % Institutions | 83.06% |
Volatility is currently contracting
Merck said on Monday it would pay up to $2.13 billion under a global licensing deal with China's SciBrunch Therapeutics for rights to develop, manufacture and sell an experimental cancer treatment.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and SciBrunch Therapeutics Co., Ltd. (“SciBrunch”), today announced that they have entered into an exclusive global license agreement for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor.“Evidence continues to accumulate for the therapeutic potential of targeting the KRAS pathway, a well-characterized factor in tumor cell growth,” said George Addona, senior vice president,.
RAHWAY, N.J.--(BUSINESS WIRE)--The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck's (NYSE: MRK), known as MSD outside of the United States and Canada, ifinatamab deruxtecan (I-DXd) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy has been voluntarily withdrawn. The decision to withdraw the BLA is based on discussions wit.
MRK's remigromig meets the primary goal in a DME study, showing non-inferiority to ranibizumab while further safety analyses continue.
RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves WELIREG Plus LENVIMA for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC).
Exelixis faces a three-month FDA review delay for zanzalintinib, pushing the potential CRC decision to March 2027.
Merck & Co Inc (NYSE:MRK, XETRA:6MK) could see its shares re-rated as a series of clinical catalysts across its oncology and broader pipeline approach over the next 12 to 18 months, Bank of America (BofA) said while maintaining its 'buy' rating. The bank hosted investor meetings with Merck chief medical officer Eliav Barr, who conveyed confidence in the company's pipeline, with oncology and other programs providing multiple potential value-driving data readouts.
Patent cliffs have buried lesser pharma dividends, yet these four Big Pharma giants keep raising payouts despite losing blockbuster exclusivities worth billions.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved an update to the U.S. product label for WINREVAIR™ (sotatercept-csrk) for injection, 45mg, 60mg, based on the Phase 3 HYPERION trial. WINREVAIR, an activin signaling inhibitor, is FDA-approved for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension) to improve exercise ca.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MRK and any ticker you trade — then tracks every position and per-strategy win rate.
